| Project/Area Number |
15K18990
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
ARIOKA Masaki 九州大学, 医学研究院, 助教 (20733554)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | GSK3 / GSK3阻害薬 / 炎症 / 骨再生 / 腎不全 / GSK阻害薬 / 破骨細胞 |
|---|
| Outline of Final Research Achievements |
SB216763 inhibited the strongest osteoclast differentiation. Moreover, the GSK3 inhibitors might inhibit osteoclast differentiation by suppressing the production of PBE2 through inhibition of COX-2 and mPGES-1. In response to the effect on osteoblasts, SB216763 resulted in promoting the most calcification.Although systemic administration of GSK3 inhibitors promotes bone formation, it was not known whether it is effective in patients with renal failure. Oral administration of lithium increases trabecular bone mass using adenine-induced uremic mice. It would be necessary to investigate the effect of other specific GSK3 inhibitors and study of the drug delivery system for local administration.Inhibiting activation of GSK3 would promote bone regeneration. On the other hand, we must also be concerned about the risk of cancer progression. Differentiation inducing factor-1, GSK3 activator, suppressed cancer proliferation / infiltration.
|
